Daily Exposure to Air Pollution Particulate Matter Is Associated with Atrial Fibrillation in High-Risk Patients

Elisa Gallo 1, Franco Folino 2, Gianfranco Buja 2, Gabriele Zanotto 3, Daniele Bottigliengo 1, Rosanna Comoretto 1, Elena Marras 4, Giuseppe Allocca 4, Diego Vaccari 5, Gianni Gasparini 6, Emanuele Bertaglia 2, Franco Zoppo 7, Vittorio Calzolari 8, Rene Nangah Suh 9, Barbara Ignatiuk 10, Corrado Lanera 10, Alessandro Benassi 11, Dario Gregori 11• and Sabino Iliceto 2

1 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy; elisa.gallo@unipd.it (E.G.); daniele.bottigliengo@phd.unipd.it (D.B.); rosanna.comoretto@unipd.it (R.C.); corrado.lanera@unipd.it (C.L.)
2 Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy; franco.folino@unipd.it (F.F.); gianfranco.buja@unipd.it (G.B.); bertagliaferro@alice.it (E.B.); sabino.iliceto@unipd.it (S.I.)
3 Department of Cardiology, Mater Salutis Hospital, 37045 Legnago, Italy; gabzanot@tin.it
4 Department of Cardiology, S Maria dei Battuti Hospital, 31015 Conegliano, Italy; elena.marras@alice.it (E.M.); alloccag75@libero.it (G.A.)
5 Department of Cardiology, Civic Hospital, 31044 Montebelluna, Italy; vaccaridiego@gmail.com
6 Department of Cardiology, Dell’Angelo Hospital, 30174 Mestre, Italy; g_gasparini2000@yahoo.it
7 Department of Cardiology, Civic Hospital, 30035 Mirano, Italy; francozoppo@gmail.com
8 Department of Cardiology, Ca’ Foncello Hospital, 31100 Treviso, Italy; toio.calzolari@gmail.com
9 Department of Cardiology, Civic Hospital, 30026 Portogruaro, Italy; renenangah@yahoo.com
10 Department of Cardiology, Civic Hospital, 35043 Monselice, Italy; barbara.ignatiuk@fastwebnet.it
11 Regional Agency for Environmental Prevention and Protection of the Veneto Region, 35121 Padua, Italy; alessandro.benassi@regione.veneto.it
* Correspondence: dario.gregori@unipd.it; Tel.: +39-049-8275384

Received: 8 July 2020; Accepted: 12 August 2020; Published: 19 August 2020

Abstract: Several epidemiological studies found an association between acute exposure to fine particulate matter of less than 2.5 µm and 10 µm in aerodynamic diameter (PM_{2.5} and PM_{10}) and cardiovascular diseases, ventricular fibrillation incidence and mortality. The effects of pollution on atrial fibrillation (AF) beyond the first several hours of exposure remain controversial. A total of 145 patients with implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy defibrillators (ICD-CRT), or pacemakers were enrolled in this multicentric prospective study. Daily levels of PM_{2.5} and PM_{10} were collected from monitoring stations within 20 km of the patient’s residence. A Firth Logistic Regression model was used to evaluate the association between AF and daily exposure to PM_{2.5} and PM_{10}. Exposure levels to PM_{2.5} and PM_{10} were moderate, being above the World Health Organization (WHO) PM_{2.5} and PM_{10} thresholds of 25 µg/m³ and 50 µg/m³, respectively, on 26% and 18% of the follow-up days. An association was found between daily levels of PM_{2.5} and PM_{10} and AF (95% confidence intervals (CIs) of 1.34–2.40 and 1.44–4.28, respectively) for an increase of 50 µg/m³ above the WHO threshold. Daily exposure to moderate PM_{2.5} and PM_{10} levels is associated with AF in patients who are not prone to AF.

Keywords: atrial fibrillation; air pollution; cardiovascular risk
1. Introduction

The effects of air pollution on overall mortality and on cardiovascular mortality have been well documented [1,2]. Specifically, particulate matter has been linked to an increased risk of myocardial infarction [3] and ventricular fibrillation [4], whereas its relationship with atrial fibrillation (AF) has not been completely clarified yet. AF is the most common arrhythmia, affecting 4.5 million people in Europe [5], and its prevalence is projected to increase in the next years [6]. Moreover, AF is associated with an increased risk of hospitalization and stroke [7,8].

In the last two decades, some epidemiological studies evaluated the association between short-term exposure to air pollution and AF with two main approaches: analyzing hospital admissions [9–12] or enrolling subjects for whom continuous monitoring of the heart rhythm was possible (i.e., patients with implantable devices or subjects that underwent a Holter screening) [13–15]. Evidence of an association between AF onset and an increase in particulate matter of less than 2.5 µm in aerodynamic diameter (PM$_{2.5}$) concentration in the 2 h prior to AF has been demonstrated by Link and colleagues [13] and for the whole day by Liu and colleagues [16]. Moreover, in a healthy community-dwelling sample of nonsmokers, AF predictors were found to be associated with increased levels of PM$_{2.5}$ [17], and lagged alterations in the ECG were found in association with PM$_{2.5}$ in patients undergoing catheterization [15].

Contrariwise, controlled exposure studies in both healthy volunteers and patients with coronary heart disease have not shown any pro-arrhythmic effect of air pollution [18], whereas a positive but not statistically significant association was found between PM$_{2.5}$ exposure and hospitalization for both AF [19] and paroxysmal atrial fibrillation episodes [20]. Moreover, some studies on hospitalization rates for AF found an association with PM [9,10,16], whereas others highlighted a lack of association [11,12].

The present study aimed to enhance the knowledge about the potential association between PM exposure and AF in patients with implanted devices, such as cardiac resynchronization therapy defibrillators (ICD-CRT), implantable cardioverter defibrillators (ICD), or pacemakers, that allow for the detection of AF episodes.

2. Materials and Methods

2.1. Patient Sample

Subjects were selected from the ARIA study cohort [4], consecutively recruited from patients followed in nine different cardiological centers in the Veneto Region in the northeast of Italy.

Inclusion criteria were: aged at least 18 years old, having been implanted with an Evia© or Estella© pacemaker, with a Lumax© ICD-CRT, or with an ICD (Biotronik, Berlin, Germany). The system had to be compatible with a remote monitoring system with daily data transmission, and the patient’s residence had to be within 20 km of the pollution monitoring station. Patients were recruited between 1 April 2011, and 30 September 2012, with a minimum follow-up of 1 year. Then, the patients were scheduled to have a closing visit within 1 subsequent year.

As in a previously published work on the same study cohort [4], patients were excluded if they had clinically manifested heart failure, concomitant illness or a severe disorder that severely limited life expectancy; any medical or surgical disorder that, at the discretion of the investigator, placed the patient at high risk for adverse clinical events for participation in the study; a previous 2-year history of malignancy of any organ system, regardless of whether it was treated, including leukemia and lymphoma (with the exception of basal cell carcinoma of the skin), if there was evidence of local recurrence of metastasis; a history of drug or alcohol abuse in the last 2 years.

All patients who complied with these criteria were included. A first analysis focused only on patients with fewer than 6 AF episodes in a year to exclude patients with frequent AF. Patients with a higher number of AF events per year were included in a secondary analysis. This study is registered with ClinicalTrials.gov, number NCT01723761.
2.2. Procedures

Diagnostic data recorded by the device during the day were transmitted daily to a mobile transmitter placed in the patient’s house. This transmitter sent data in turn through a Global System for Mobile Communications network to the Biotronik Home Monitoring Service Center where the data could be examined by physicians.

Biotronik detected AF in its devices as “Atrial Burden” (AB), i.e., the percentage of time a patient was in AF during the day. An AB detected by the device, in which the time a patient was in AF throughout one day was $\geq 0.5\%$, was considered as an AF event.

2.3. Environmental Data

Daily PM$_{2.5}$ and PM$_{10}$ concentrations were obtained from permanent monitoring stations of the Regional Agency for Environmental Prevention and Protection of the Veneto Region (ARPAV), located throughout the Veneto region of Italy. In addition, median daily values of temperature, humidity, and pressure were collected from the meteorological center of the same agency, and they were considered as possible confounders.

Patients were associated with exposure data from the monitoring station that was nearest to their residence.

2.4. Statistical Analyses

Continuous variables are expressed as median (I and III quartiles), whereas categorical variables are represented with frequencies (percentages). In the present study, AB equal to 0 was labeled as an absence of AB, whereas AB greater than 0 was the presence of AB.

A multivariable logistic model was implemented to assess the effects of the daily level of PM$_{2.5}$ and PM$_{10}$ on the risk of AB. Models were adjusted for three groups of variables: (i) environmental variables, i.e., the median daily levels of humidity, pressure, and temperature; (ii) clinical variables, i.e., $\beta$-blocker therapy and antiarrhythmics drugs; (iii) demographical variables, i.e., age and sex. The association between pollutants and AB was flexibly modeled with a restricted cubic spline function to allow for potential nonlinear relationships. A robust sandwich variance estimator was used to account for repeated measurements of the same subjects during follow-up [21]. Firth’s bias reduction method, which produces finite parameter estimates by means of a penalized maximum likelihood estimation, was used to reduce the bias introduced in the coefficients’ estimates of the logistic model by the small number of events [22,23]. The association was evaluated first in patients with fewer than 6 events per year.

Different sets of patients were considered in a second analysis to evaluate how the estimated association was sensitive to the AB episodes inclusion criterion. The models were fitted on different samples of patients obtained by increasing the number of AB episodes per patient per year. The relationship between the number of AB episodes per patient per year and the association between AB and PM was then assessed.

As sensitivity analyses, we performed distributed lag models [24], including the lag from 0 to 2 of the pollutants, temperature, pressure, and humidity on the population with fewer than 6 AB episodes.

Results are represented as Odds Ratio (OR) and relative 95% Confidence Interval (CI) for an increase in the pollutant concentration of 50 $\mu g/m^3$ over the WHO threshold. All of the analyses were implemented with R-System [25]. The rms [26] and brglm [27] libraries were used to fit the models.

3. Results

A total of 145 patients living in 137 municipalities of the Veneto region were included in the study cohort. The clinical features of the patients are presented in Table 1.
Table 1. Baseline patient characteristics.

|                              | Patients (n = 145) |
|------------------------------|-------------------|
| Men                          | 109 (75.2)        |
| Age (years)                  | 72.00 [64.00, 77.00] |
| Smokers                      | 12 (8.3)          |
| Hypertensive cardiomyopathy  | 16 (11.0)         |
| Myocardial infarction        | 40 (27.6)         |
| Valvular heart disease       | 6 (4.1)           |
| Dilated cardiomyopathy       | 45 (31)           |
| Hypertrophic cardiomyopathy  | 2 (1.4)           |
| **Treatments**               |                   |
| Antiarrhythmics drugs        | 29 (20.0)         |
| β-blockers                   | 81 (55.9)         |
| ACE inhibitors               | 68 (46.9)         |
| Diuretics                    | 74 (51.0)         |
| Spirolactone                 | 8 (5.5)           |
| Calcium-antagonists          | 21 (14.5)         |
| α-blockers                   | 3 (2.1)           |
| Ivabradine                   | 1 (0.7)           |
| Digitalis                    | 5 (3.4)           |
| Nitrates                     | 7 (4.8)           |
| Antiplatelet                 | 73 (50.3)         |
| Oral anticoagulant           | 31 (21.4)         |
| NYHA class                   |                   |
| I                            | 45 (51.1)         |
| II                           | 35 (39.8)         |
| III                          | 8 (9.1)           |
| IV                           | 0                 |
| **Comorbidities**            |                   |
| Hypertension                 | 70 (48.3)         |
| Diabetes                     | 30 (20.7)         |
| Kidney failure               | 8 (5.5)           |
| Previous stroke or TIA       | 11 (7.6)          |
| Chronic Obstructive Pulmonary Disease | 12 (8.3) |

Data are n (%) or median [IQR]. NYHA = New York Heart Association. ACE = Angiotensin-Converting Enzyme. TIA = Transient Ischemic Attack.

PM$_{2.5}$ exceeded the World Health Organization (WHO) threshold of 25 µg/m$^3$ for 26% of the days, whereas PM$_{10}$ was detected above the threshold of 50 µg/m$^3$ for 18% of the days during the follow-up (Table 2).

Table 2. Pollutants data.

| Pollutants   | Days PM$_{2.5}$ over the threshold | PM$_{2.5}$ (µg/m$^3$) | Days PM$_{10}$ over the threshold | PM$_{10}$ (µg/m$^3$) |
|--------------|-----------------------------------|-----------------------|----------------------------------|----------------------|
| PM$_{2.5}$   | 9697 (26.2%)                      | 16.00 [10.00, 26.00]  | 3704 (18.3%)                     | 26.00 [15.50, 42.50]  |
| PM$_{10}$    |                                   |                       |                                  |                      |

Data are median [IQR] or n (%). PM$_{2.5}$ and PM$_{10}$ are particulate matter of less than 2.5 µm and 10 µm in aerodynamic diameter, respectively.

Overall, 26 episodes of AB were observed. The odds ratios (OR) of the models indicated a significant association between AB and daily levels of both PM$_{2.5}$ and PM$_{10}$ (Table 3).

Univariable logistic model for pollutants modeled with a restricted cubic spline; logistic model with Firth’s correction adjusted for antiarrhythmic and β-blockers therapy, age, sex, median daily pressure, temperature and humidity.

The risk of AB onset increases nonlinearly for concentrations above the WHO thresholds. PM$_{2.5}$ and PM$_{10}$ seem to increase the AB risk, mostly at higher concentrations (Figure 1).
Table 3. Estimated effects of pollutants on atrial burden.

| Effects        | Odds Ratio | 95% CI     | p-Value (Nonlinearity) |
|----------------|------------|------------|------------------------|
| **Univariable model** |            |            |                        |
| PM<sub>2.5</sub> 75 vs. 25 | 1.98       | 1.22–3.22  | 0.002                  |
| PM<sub>10</sub> 100 vs. 50    | 2.64       | 1.02–6.83  | 0.249                  |
| **Adjusted model and Firth corrected** |            |            |                        |
| PM<sub>2.5</sub> 75 vs. 25 | 1.80       | 1.34–2.40  | 0.01                   |
| PM<sub>10</sub> 100 vs. 50    | 2.48       | 1.44–4.28  | 0.01                   |

PM<sub>2.5</sub> and PM<sub>10</sub> are particulate matter of less than 2.5 µm and 10 µm in aerodynamic diameter, respectively.

Figure 1. Plot of the estimated daily probability of atrial burden (AB) at different concentrations of particulate matters of less than 2.5 µm (PM<sub>2.5</sub>) and less than 10 µm (PM<sub>10</sub>) in aerodynamic diameter.

In a second analysis, the risk of AB in association with PM was evaluated by consecutively increasing the number of AB episodes per year considered, with the consequent increase in population size (Figure 2). On the x-axis, the number of AB episodes per year is reported. Each point on the x-axis corresponds to different sets of subjects with a given number of AB episodes in a year. On the y-axis, the ORs with relative 95% CIs for a given set of subjects are depicted.

Including up to 365 AB episodes in a year, the total number of patients considered for the analysis was 201 and the total number of AB episodes recorded was 13,760. The value that identifies a statistically significant association between PM and the risk of AB was found to be eight AB episodes during a year. Therefore, if a patient experiences fewer than eight episodes, the association is positive and statistically significant for both PM<sub>2.5</sub> and PM<sub>10</sub>, whereas if the number of episodes is greater to or equal to eight, air pollution seems not to affect the risk of AB (Figure 2).
Sensitivity analyses showed that the significant effect of PM$_{10}$ and PM$_{2.5}$ on AB risk is present at lag 0, whereas no significant effect is shown for air pollution at lags from 1 to 2 (Table 4).

![Graph](image)

**Figure 2.** Increasing number of atrial burden (AB) episodes considered in the analysis and relative OR and confidence interval (in gray) for particulate matters of less than 10 $\mu$m (PM$_{10}$) (a) and less than 2.5 $\mu$m (PM$_{2.5}$) (b) in aerodynamic diameter.

**Table 4.** Firth’s logistic regression with delayed effects in time analyzed with a distributed lag model.

| Pollutant | Effect | OR (95% CI) Lag 0 | OR (95% CI) Lag 1 | OR (95% CI) Lag 2 |
|-----------|--------|------------------|------------------|------------------|
| PM$_{2.5}$ | 75 vs. 25 | 3.46 (1.36–8.74) | 1.42 (0.56–3.59) | 1.21 (0.70–2.10) |
| PM$_{10}$  | 100 vs. 50 | 3.74 (2.52–5.55) | 1.48 (0.90–2.42) | 0.69 (0.44–1.06) |

4. Discussion

In this multicentric longitudinal study of patients implanted with an ICD, an ICD-CRT, or a pacemaker, an association was found between AB and daily levels of both PM$_{2.5}$ and PM$_{10}$. By recruiting patients with these types of devices, it was possible to also capture asymptomatic AF.

Our results are in line with those of other epidemiological and observational investigations that found an association between PM exposure and AF. In fact, it has been observed there is a significant association between AB and daily levels of both PM$_{2.5}$ and PM$_{10}$. The first evidence of the role of air pollution in triggering AF has been highlighted by Liao and colleagues [17]. Acute exposure to PM$_{2.5}$ was indeed found to be associated with predictors of AF with more complex P-wave morphology and PR duration in a sample of subjects without severe cardiac problems [17].
A recent study conducted in China on patients who had cardiac implantable electronic devices showed an increased risk of AF onset in association with high levels of PM$_{2.5}$ and PM$_{10}$ [16]. Moreover, two studies found an association between air pollution and cardiac arrhythmias’ hospitalizations [10,28], and both reported that the average air pollution concentrations recorded in the study period exceeded the WHO thresholds. Conversely, the study conducted by Rich and colleagues in a less polluted area observed a positive but nonsignificant increased risk between paroxysmal atrial fibrillation and PM$_{2.5}$ in ICD implanted patients [20]. Link and colleagues found a significant association between AF and increased levels of PM$_{2.5}$ in the 2 h prior to the AF onset, only looking at the highest quartile of PM values distribution [13], thus supporting the hypothesis that PM only increases the risk of arrhythmias at medium to high PM concentrations.

Nevertheless, some studies focused on AF hospitalizations did not find an association between increased PM concentration and the risk of hospitalization [11,12,19]. In these studies, the outcome definition did not include people with asymptomatic AF, and the target population was the general population, not exclusively high-risk subjects. Indeed, patients implanted with ICDs, ICD-CRT, or pacemakers could be defined as high-risk, as they might be more susceptible to air pollution due to their underlying pathological condition [19].

The primary analyses conducted in this paper were focused on patients with a maximum of six AB episodes in a year in order to exclude patients in which a frequent AB onset could be mostly related to electric remodeling phenomena and not to air pollution. Therefore, in subjects with persistent or permanent AB, the effects of air pollution on AB onset could be underestimated.

To assess this hypothesis, the role of air pollution on the risk of AB occurrence was evaluated in an increasing number of patients by also considering the ones first excluded because of their high number of AB episodes in a year. In this way, the analysis was repeated 365 times, starting from patients who had only one AB episode per year and including progressively more patients until finally considering patients with 365 events per year. The results showed that for both PM$_{2.5}$ and PM$_{10}$ there was a significant positive effect on AB occurrence from one episode to seven episodes considered per year.

This result is in accordance with what was already reported in the literature [13], where PM seems to play a role only in patients with infrequent AF episodes. Furthermore, Link and colleagues found a statistically significant association between PM$_{2.5}$ and AF onset in ICD-implanted patients with fewer than 20 episodes, and when looking at the whole population, the association was still positive but nonsignificant [13].

Mechanisms through which PM could lead to AF have not been completely understood so far. One major hypothesis is that inhaled PM activates sensory receptors in the lungs, leading to alterations in the autonomic tone that could result in an increased risk of arrhythmias [29,30]. Furthermore, it has been hypothesized that PM triggers inflammation and oxidative stress [31]. In particular, exposure to air pollution seems to increase the levels of C-reactive protein [32] that are, in turn, associated with an increased risk of developing AF [33,34].

The wide range of results reported in these years may be due to the different concentration levels of ambient PM, different components of PM, population susceptibility, and number of AF episodes per year considered, but a common theme is now emerging.

Study Limitations

This study has some limitations. First, aiming to evaluate the effects of PM in patients who have infrequent AB episodes meant that the patient sample was limited. Moreover, the low number of AB episodes per patient per year considered in the first analysis led to a low number of total AB episodes observed. However, this problem was addressed using a logistic regression model with Firth’s correction, which reduced the bias in the maximum likelihood estimates of coefficients and consequently led to a more accurate stratification of the risk. Additionally, this statistical approach minimized the potential impact on estimates that may occur in such situations by specifically addressing
the inflation of observations not associated with an event of interest. As persistent AB is mainly due to 
underlying pathologies, the real effect of air pollution on this subgroup cannot be estimated.

Moreover, no interactions between patients’ therapies were tested, and other possible confounding 
variables such as pulmonary disease, physical activity, vulnerability status or exposure to other 
pollutants have not been included.

The possible exposure misclassification due to the use of fixed monitoring stations that do not 
represent the real-time exposure of patients was partially controlled by the homogeneous distribution 
of PM in the Veneto region because of its morphological conditions. Moreover, the age of the patients 
suggests that most of them were not still working, so their movements due to work were limited. 
As such, the theoretical exposure was assumed to be at least 8 h.

5. Conclusions

In the current study, an association was found between AF and moderate air pollution exposure 
to both PM$_{2.5}$ and PM$_{10}$ in patients implanted with ICDs, ICD-CRT, and pacemakers with few episodes 
of AF. This finding is in accordance with studies indicating that there was a positive and significant 
association with high-moderate levels of pollutants.

Author Contributions: Conceptualization, F.F., D.G. and S.I.; Formal analysis, E.G. and D.B.; Investigation, 
G.B.; Methodology, D.B. and C.L.; Resources, G.Z., E.M., G.A., D.V., G.G., E.B., F.Z., V.C., R.N.S., B.I. and A.B.; 
Supervision, D.G. and S.I.; Writing, original draft, E.G.; Writing, review & editing, F.F., D.B., R.C. and D.G. 
All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We thank the Regional Agency for Environmental Prevention and Protection of the Veneto 
Region (ARPAV) for providing meteorological and exposure data and Biotronik Italy for technical support for the 
data management. The study took place in the following participating centers: Department of Cardiac, Thoracic, 
Vascular Sciences and Public Health, University of Padua, Padua, Italy; Department of Cardiology Mater Salutis 
Hospital, Legnago, Italy; Department of Cardiology, S Maria dei Battuti Hospital, Conegliano, Italy; Department 
of Cardiology, Civic Hospital, Montebelluna, Italy; Department of Cardiology, Dell’Angelo Hospital, Mestre, 
Italy; Department of Cardiology, Civic Hospital, Mirano, Italy; Department of Cardiology Ca’ Foncello Hospital, 
Treviso, Italy; Department of Cardiology, Civic Hospital, Portogruaro, Italy; and Department of Cardiology, 
Civic Hospital, Monselice, Italy. The Clinical Event Committee comprised Gianfranco Buja, Barbara Ignatiuk and 
Michela Maddalosso.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AB = atrial burden
AF = atrial fibrillation
CI = confidence interval
ICD = implantable cardioverter-defibrillator
ICD-CRT = cardiac resynchronization therapy defibrillators
IQR = interquartile range
OR = Odds Ratio
PM$_{2.5}$ = particulate matter of less than 2.5 $\mu$m in aerodynamic diameter
PM$_{10}$ = particulate matter of less than 10 $\mu$m in aerodynamic diameter
WHO = World Health Organization

References

1. Chen, R.; Yin, P.; Meng, X.; Liu, C.; Wang, L.; Xu, X.; Ross, J.A.; Tse, L.A.; Zhao, Z.; Kan, H.; et al. Fine 
Particulate Air Pollution and Daily Mortality: A Nationwide Analysis in 272 Chinese Cities. *Am. J. Respir.
Crit. Care Med.* **2017**, *196*, 73–81. [CrossRef] [PubMed]
2. Di, Q.; Dai, L.; Wang, Y.; Zanobetti, A.; Choirat, C.; Schwartz, J.; Dominici, F. Association of Short-term 
Exposure to Air Pollution With Mortality in Older Adults. *JAMA* **2017**, *318*, 2446–2456. [CrossRef] [PubMed]
3. Wu, Y.; Li, M.; Tian, Y.; Cao, Y.; Song, J.; Huang, Z.; Wang, X.; Hu, Y. Short-Term effects of ambient fine particulate air pollution on inpatient visits for myocardial infarction in Beijing, China. *Environ. Sci. Pollut. Res.* 2019, **26**, 14178–14183. [CrossRef] [PubMed]

4. Folino, F.; Buja, G.; Zanotto, G.; Marras, E.; Allocca, G.; Vaccari, D.; Gasparini, G.; Bertaglia, E.; Zoppi, F.; Calzolari, V.; et al. Association between air pollution and ventricular arrhythmias in high-risk patients (ARIA study): A multicentre longitudinal study. *Lancet Planet. Health* **2017**, **1**, e58–e64. [CrossRef]

5. Fuster, V.; Rydén, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; Halperin, J.L.; Kay, G.N.; Le Huezey, J.-Y.; Lowe, J.E.; et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. *J. Am. Coll. Cardiol.* **2011**, **57**, e101–e198. [CrossRef]

6. Krijthe, B.P.; Kunst, A.; Benjamin, E.J.; Lip, G.Y.; Franco, O.H.; Hofman, A.; Witterman, J.C.; Stricker, B.H.; Heeringa, J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur. Hear. J.* **2013**, **34**, 2746–2751. [CrossRef]

7. Benjamin, E.J.; Wolf, P.A.; D’Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. *Circulation* **1998**, **98**, 946–952. [CrossRef]

8. Wolf, P.A.; Mitchell, J.B.; Baker, C.S.; Kannel, W.B.; D’Agostino, R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. *Arch. Intern. Med.* **1998**, **158**, 229–234. [CrossRef]

9. Solimini, A.G.; Renzi, M. Association between Air Pollution and Emergency Room Visits for Atrial Fibrillation. *Int. J. Environ. Res. Public Health* **2017**, **14**, 661. [CrossRef]

10. Lee, H.H.; Pan, S.C.; Chen, B.Y.; Lo, S.H.; Guo, Y.-L.L. Atrial fibrillation hospitalization is associated with exposure to fine particulate air pollutants. *Environ. Health* **2019**, **18**, 117–118. [CrossRef]

11. Saifipour, A.; Azhari, A.; Pourmohaghad, A.; Hosseini, S.M.; Jafari-Koshki, T.; Rahimi, M.; Nasri, A.; Shishehforoush, M.; Lahijanzadeh, A.; Sadeghian, B.; et al. Association between ambient air pollution and hospitalization caused by atrial fibrillation. *ARVA Atheroscler.* **2019**, **15**, 106–112. [CrossRef] [PubMed]

12. Kwon, O.K.; Kim, S.-H.; Kang, S.-H.; Cho, Y.; Oh, I.-Y.; Yoon, C.-H.; Kim, S.-Y.; Kim, O.-J.; Choi, E.-K.; Youn, T.-J.; et al. Association of short- and long-term exposure to air pollution with atrial fibrillation. *Eur. J. Prev. Cardiol.* **2019**, **26**, 1208–1216. [CrossRef] [PubMed]

13. Link, M.S.; Luttmann-Gibson, H.; Schwartz, J.; Mittleman, M.A.; Wessler, B.; Gold, D.R.; Dockery, D.W.; Laden, F. Acute Exposure to Air Pollution Triggers Atrial Fibrillation. *J. Am. Coll. Cardiol.* **2013**, **62**, 816–825. [CrossRef] [PubMed]

14. Dockery, D.W.; Luttmann-Gibson, H.; Rich, D.Q.; Link, M.S.; Schwartz, J.D.; Gold, D.R.; Koutrakis, P.; Verrier, R.L.; Mittleman, M.A. Particulate air pollution and nonfatal cardiac events. Part II. Association of air pollution with confirmed arrhythmias recorded by implanted defibrillators. *Res. Rep. Health Eff. Inst.* **2005**, **124**, 83–126.

15. Zhang, S.; Breitner, S.; Cascio, W.E.; Devlin, R.B.; Neas, L.M.; Diaz-Sanchez, D.; Kraus, W.E.; Schwartz, J.; Hauser, E.R.; Peters, A.; et al. Short-term effects of fine particulate matter and ozone on the cardiac conduction system in patients undergoing cardiac catheterization. *Part. Fibre Toxicol.* **2018**, **15**, 38. [CrossRef]

16. Liu, X.; Kong, D.; Liu, Y.; Fu, J.; Gao, P.; Chen, T.; Fang, Q.; Cheng, K.; Fan, Z. Effects of the short-term exposure to ambient air pollution on atrial fibrillation. *Pacing Clin. Electrophysiol.* **2018**, **41**. [CrossRef]

17. Liao, D.; Shaffer, M.L.; He, F.; Rodriguez-Colon, S.; Wu, R.; Whitsel, E.A.; Bixler, E.O.; Cascio, W.E. Fine Particulate air Pollution is Associated with Higher Vulnerability to Atrial Fibrillation—The APACR Study. *J. Toxicol. Environ. Health A* **2011**, **74**, 693–705. [CrossRef]

18. Langrish, J.P.; Watts, S.J.; Hunter, A.J.; Shah, A.S.V.; Bosson, J.A.; Unosson, J.; Barath, S.; Lundbäck, M.; Cassee, F.R.; Donaldson, K.; et al. Controlled Exposures to Air Pollutants and Risk of Cardiac Arrhythmia. *Environ. Health Perspect.* **2011**, **119**, 747–753. [CrossRef]

19. Bunch, T.J.; Horne, B.D.; Asirvatham, S.J.; Day, J.D.; Crandall, B.G.; Weiss, J.P.; Osborn, J.S.; Anderson, J.L.; Muhlestein, J.B.; Lappe, D.L.; et al. Atrial Fibrillation Hospitalization Is Not Increased with Short-Term Elevations in Exposure to Fine Particulate Air Pollution. *Pacing Clin. Electrophysiol.* **2011**, **34**, 1475–1479. [CrossRef]

20. Rich, D.Q.; Mittleman, M.A.; Link, M.S.; Schwartz, J.; Luttmann-Gibson, H.; Catalano, P.J.; Speizer, F.E.; Gold, D.R.; Dockery, D.W. Increased Risk of Paroxysmal Atrial Fibrillation Episodes Associated with Acute Increases in Ambient Air Pollution. *Environ. Health Perspect.* **2006**, **114**, 120–123. [CrossRef]
21. White, H. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. *Econometrica* **1980**, *48*, 817–838. [CrossRef]

22. Firth, D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika* **1993**, *80*, 207–23. [CrossRef]

23. Heinze, G.; Schmper, M. A solution to the problem of separation in logistic regression. *Stat. Med.* **2002**, *21*, 2409–2419. [CrossRef]

24. Bhaskaran, K.; Gasparrini, A.; Hajat, S.; Smeth, L.; Armstrong, B. Time series regression studies in environmental epidemiology. *Int. J. Epidemiol.* **2013**, *42*, 1187–1195. [CrossRef] [PubMed]

25. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2019.

26. Harrell, F.E.J. Rms: Regression Modeling Strategies. R Package Version 5.1-0. 2017. Available online: https://CRAN.R-project.org/package=rms (accessed on 10 June 2020).

27. Kosmidis, I. Brglm: Bias Reduction in Binomial-Response Generalized Linear Models. Available online: https://cran.r-project.org/package=brglm (accessed on 10 June 2020).

28. Zheng, Q.; Liu, H.; Zhang, J.; Chen, D. The effect of ambient particle matters on hospital admissions for cardiac arrhythmia: A multi-city case-crossover study in China. *Environ. Health* **2018**, *17*. [CrossRef] [PubMed]

29. Bettoni, M.; Zimmermann, M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. *Circulation* **2002**, *105*, 2753–2759. [CrossRef]

30. Brook, R.D.; Franklin, B.; Cascio, W.; Hong, Y.; Howard, G.; Lipsett, M.; Mittleman, M.; Samet, J.; Smith, S.C.; et al. Air Pollution and Cardiovascular Disease. *Circulation* **2004**, *109*, 2655–2671. [CrossRef]

31. Korantzopoulos, P.; Kolettis, T.M.; Galaris, D.; Goudevenos, J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. *Int. J. Cardiol.* **2007**, *115*, 135–143. [CrossRef]

32. Hamanaka, R.B.; Mutlu, G.M. Particulate Matter Air Pollution: Effects on the Cardiovascular System. *Front. Endocrinol.* **2018**, *9*. [CrossRef]

33. Aviles, R.J.; Martin, D.O.; Apperson-Hansen, C.; Houghtaling, P.L.; Rautaharju, P.; Kronmal, R.A.; Tracy, R.; Van Wagoner, D.R.; Psaty, B.M.; Lauer, M.S.; et al. Inflammation as a Risk Factor for Atrial Fibrillation. *Circulation* **2003**, *108*, 3006–3010. [CrossRef]

34. Chung, M.K.; Martin, D.O.; Sprecher, D.; Wazni, O.; Kanderian, A.; Carnes, C.A.; Bauer, J.A.; Tchou, P.J.; Niebauer, M.J.; Natale, A.; et al. C-Reactive Protein Elevation in Patients with Atrial Arrhythmias. *Circulation* **2001**, *104*, 2886–2891. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).